Genincode Share Discussion Threads

[hedgehog 100] 03/5/2022 07:17

03/05/2022 07:02 UK Regulatory (RNS & others) GENinCode PLC Notice of Results LSE:GENI Genincode Plc

Notice of results

Analyst & investor presentations

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces it will issue its preliminary results for the year ended 31 December 2021 on Tuesday, 17 May 2022.

Matthew Walls, CEO, and Paul Foulger, CFO will host an in-person analyst meeting at the offices of Walbrook PR, 75 King William Street, London EC4N 7BE at 9.30am on 17 May. If you would like to attend, please contact Walbrook PR at [e-mail] or on 020 7933 8780.

The Company will also host a presentation for investors via the IMC platform at 3pm on 17 May. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. To register for this, please use the following link: hxxps://www.investormeetcompany.com/genincode-plc/register-investor

For more information visit www.genincode.com

[hedgehog 100] 09/4/2022 11:06

Yes, there are signs of life in the health shares sector, after a bad period.

AVCT for example has now more than doubled in a month, from about 40p to c. 100p, market cap.just over £250M.

Avacta (AVCT)

[brut winky] 09/4/2022 09:47

These look to be flying under the radar or are they just another biotech cash burner, on the positive side they actually do have a turnover unlike so many and healthcare seems to be coming into trend. Might pick a few up as they look to be bottoming out.

[hedgehog 100] 06/4/2022 16:50

06/04/2022 07:01 UK Regulatory (RNS & others) GENinCode PLC Director Appointment LSE:GENI Genincode Plc

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the appointment to the Board of Felix Frueh , PhD ("Felix") as a Non-Executive Director.

Felix is a senior life sciences executive with in-depth expertise in corporate, regulatory, and commercialisation strategies, with a particular focus on precision medicine. He has over 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He has worked in the regulatory space for 18 years, including five years working with the FDA.

In addition to his FDA career, Felix oversaw the creation and operations of the world's largest next-generation, Clinical Laboratory Improvement Amendments (CLIA)-certified, whole human genome sequencing laboratory, as the Chief Scientific Officer of Human Longevity (HLI). Prior to this, he served as President of Medco Research Institute, Research Director for Pharmacogenetics of Transgenomic, and Assistant Director of Protogene Laboratories. He is Founder and Executive Partner of Opus Three, Co-Founder and Partner of Profound Ventures, and Co-Founder and Chief Scientific Officer of Selva Therapeutics. He also co-founded and formerly served as the Chief Executive Officer of Intellos Health.

Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. He is the author of more than 100 peer-reviewed articles, book chapters, white papers, market analyses, strategies, and business plans.

Matthew Walls, CEO of GENinCode Plc commented : " We are delighted that Felix is joining as a Non-Executive Director. Felix can offer us invaluable insights into the FDA as we start to look towards commericalisation in the US later this year, and his many years of experience in key roles in the industry will be a huge benefit to us. His depth of knowledge in precision medicine and regulatory affairs is second-to-none and we are looking forward to capitalising on his expertise."

Bill Rhodes, Non-Executive Chairman of GENinCode Plc, commented: "Our goal is to improve the current standard of care in cardiovascular disease worldwide through our unique portfolio of products, and Felix has the experience and expertise to help us achieve this. I am looking forward to working with him, as is the entire GENincode team, and welcome him to the Board."

Felix Frueh , PhD added: "I am thrilled to have been asked to join the Board of GENinCode at this critical stage. I have spent most of my career in the precision medicine space and feel I can add real value to the team."

Regulatory disclosures

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Felix Wilhelm Frueh, aged 54:


Current Directorships Previous Directorships
Opus Three Partners LLC Intellos Health LLC
Selva Therapeutics Enterome SA
Bloom Science, Inc. Ariana Pharmaceuticals SA
AZCERT

As of the date of this announcement, Felix Frueh holds no ordinary shares in the capital of the Company. Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For more information visit www.genincode.com

[hedgehog 100] 25/3/2022 17:18

From GENI's AIM Admission Document dated 16 July 2021:

"The Placing will raise approximately £17.0 million (before expenses) which is currently intended to be used, primarily, to complete the planned US launch of Cardio inCode and commercialisation."






I.e. most of the IPO monies are being saved until Cardio inCode receives FDA US marketing approval, to be used for launch and commercialisation in the US (in conjunction with their partner Eversana).

[barbello] 23/3/2022 15:47

A positive RNS yet no volume. Market cap minus IPO cash is tiny....this may just be a sleeper that will suddenly wake up and reward us at some point....

[hedgehog 100] 23/3/2022 08:26

23/03/2022 07:00 UK Regulatory (RNS & others) GENinCode PLC Indiana University Medical School collaboration LSE:GENI Genincode Plc

Collaboration with Indiana University School of Medicine

Study for testing Cardio inCode-SCORE for the risk of onset of cardiovascular disease

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the Indiana University School of Medicine ("IU"). IU is the largest medical school in the US and will undertake a 'Proof of Concept' study using Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease ("ASCVD "). ASCVD accounts for over 85% of all cardiovascular disease deaths and is the leading cause of morbidity and mortality in the US and globally.

According to the Centres for Disease Control and Prevention ("CDC"), cardiovascular disease ("CVD") is the number one cause of death in the United States and the decades--long trend towards lower cardiovascular mortality rates has begun to reverse, with an increase in total mortality during recent years: hxxps://www.cdc.gov/heartdisease/facts.htm .

CVD disproportionately affects people of lower socioeconomic status, and those of non--white ethnicity. Early identification of subclinical disease in the population can lead to better primary prevention of heart attack and stroke. Current American College of Cardiology ("ACC") guidelines call for risk stratification using validated instruments, such as the US National Heart Lung and Blood Institute ("NHLBI") pooled risk cohort equation, drawing on clinical parameters readily available such as blood pressure and cholesterol levels. In addition, the guidelines endorse the use of "risk enhancing factors" such as the Coronary Artery Calcium ("CAC") score, undertaken using computerised tomography ("CT") imaging of the coronary arteries.

Whilst acknowledging family history as a risk factor, current guidelines have not yet incorporated the potential of genetic risk assessment in the prediction of ASCVD. Cardio inCode-SCORE provides an opportunity to apply advanced polygenic testing to improve patient risk assessment and prognosis, in a widely available form and at reduced cost compared with other test modalities.

The primary aim of the IU study is to evaluate the association between the Cardio inCode-SCORE genetic risk score ("GRS") and the presence of subclinical coronary atherosclerosis evaluated by CAC.

CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischemia, and some chronic kidney disease) and venous thromboembolism. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. According to the US National Institutes of Health ("NIH"), by 2030, the global cost of CVD is set to rise to US$1,044 billion, from approximately US$863 billion in 2010, and is both a major health issue and global economic burden.

GENinCode has a vision to assist clinicians and inform patients about cardiovascular risk, and to improve public health using the predictive capability of genomics. High genetic risk patients are assisted in making lifestyle choices and can receive targeted treatment to improve outcomes. Over the past 15 years , GENinCode has made a substantial investment in its research, bioinformatic data, technology, and product development to assess disease risk, in order to help clinicians and patients prevent the onset of CVD.

Matthew Walls, CEO, GENinCode said: "We are delighted to work with the IU School of Medicine and to introduce Cardio inCode-SCORE to the IU health community. The IU study follows on from our recently published US clinical performance studies showing the substantive predictive capability of the Cardio inCode-SCORE product for the risk assessment of patients for the onset of cardiovascular disease. We look forward to working closely with the IU team to successfully deliver the programme ."

Richard Kovacs MD, Q.E. and Sally Russell Professor of Cardiology in the Division of Cardiovascular Disease at IU School of Medicine commented: "The GENinCode and IU collaboration offers the potential to improve the prediction of ASCVD and better assess patient risk of future CVD events. GRS's provide an opportunity to enhance assessment of risk based on 'classic' CVD risk factors and help physicians identify patients at higher inherited genetic risk, thereby targeting improved treatment and reduction in future CVD events. IU welcomes this approach and we look forward to working with Cardio inCode-SCORE to advance preventative CVD care."

For more information visit www.genincode.com

[hedgehog 100] 15/3/2022 10:04

15/03/2022 07:00 UK Regulatory (RNS & others) GENinCode PLC Lipid inCode pilot LSE:GENI Genincode Plc

NHS pilot for polygenic testing of UK patients suffering with hypercholesterolemia and familial hypercholesterolemia

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces a collaboration with the Academic Health Science Network for the North East and North Cumbria ("AHSN NENC") to pilot the use of its Lipid inCode(R) test for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia ("FH").

There are 15 Academic Health Science Networks ("AHSN") across England, established by NHS England in 2013 to spread innovation at pace and scale - improving health and generating economic growth. Each AHSN works across a distinct geography serving a different population in each region. The AHSN NENC leads a national AHSN programme aimed at identification of FH and lipid management, in collaboration with the Accelerated Access Collaborative (AAC) and the National Institute for Health & Care Excellence (NICE).

The launch of Lipid inCode(R) marks the introduction of GENinCode's first UK polygenic product aimed at improving the diagnosis and treatment of hypercholesterolemia and preventing the onset of cardiovascular disease ("CVD").

Following the successful completion and positive results of its NHS clinical study (1) of the Lipid inCode(R) test, the AHSN NENC collaboration will undertake a short term pilot using Lipid inCode(R) in primary care and community practice to help in the detection and diagnosis of people with high cholesterol, a known important risk factor for the development of CVD. Improved detection will also support better treatment and preventative care. Lipid inCode(R) offers genetic testing for the causes of high cholesterol, with rapid results and a comprehensive report provided to clinicians. Lipid inCode(R) will be offered at a reduced cost to the NHS to help support its declared ambition to detect 25% of people with FH by 2024.

In the UK around 7.6m people live with heart and circulatory disease, which causes 25% of all deaths annually in the UK. CVD can be reduced by identifying and treating individuals at risk, and the NHS 10 Year Plan (2019) sets out significant ambitions to address the CVD prevention, including identifying individuals with hypercholesterolemia and particularly those with FH.

FH is an inherited monogenic condition which affects an individual's ability to regulate and remove cholesterol from their blood. FH affects approximately 1 in 250 people in the UK population and globally. The NHS Long Term Plan sets out to expand access to genetic testing for FH, which causes early heart attacks and sudden cardiac death. Individuals suffering with FH have a higher risk of heart disease and death at a younger age. For individuals suffering with FH it is important to lower their cholesterol to healthy levels as early in life as possible, often requiring medicines such as statins or more aggressive treatment to help better control cholesterol levels.

CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischemia, and some chronic kidney disease) and venous thromboembolism. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. According to the US National Institutes of Health (NIH), by 2030, the global cost of CVD is set to rise to US$1,044 billion, from approximately US$863 billion in 2010, and is both a major health issue and global economic burden.

GENinCode has a vision to assist clinicians and inform patients in interpreting cardiovascular risk, and to improve public health using the predictive capability of genomics. High genetic risk patients are assisted in making lifestyle choices and can receive targeted treatment to improve outcomes. Over the past 15 years GENinCode has made a substantial investment in its research, bioinformatic data, technology, and product development to assess disease risk, in order to help clinicians and patients prevent the onset of CVD.

Matthew Walls, CEO, GENinCode said: "The AHSN NENC pilot marks the beginning of our Lipid inCode(R) diagnostic testing for hypercholesterolemia and familial hypercholesterolemia sufferers and we look forward to supporting the NHS in reaching its goals to diagnose patients with hypercholesterolemia."

Professor Julia Newton, Medical Director at AHSN NENC commented: "We are delighted to pilot Lipid inCode(R) to advance the diagnosis and treatment of hypercholesterolemia and familial hypercholesterolemia. With the added benefit of easy sample collection, improved test turnaround times and at reduced costs to the NHS, we welcome this approach to help support and deliver the NHS 10-Year plan to reduce the onset of cardiovascular disease."

For more information visit www.genincode.com

[barbello] 08/2/2022 09:24

Just topped up at 40% discount to recent IPO where they raised about £17m so current market cap of £26m including cash looks attractive to me esp after some useful validation.

[albert arthur] 08/2/2022 08:03

Nice news this AM :)

[toffeeman] 08/2/2022 07:44

Well - reassuring RNS - but it would have been a disaster if the trial had not worked!

[hedgehog 100] 27/1/2022 17:12

diversification 10 Sep '21 - 16:52 - 12 of 56 0 1 0
"'@Stifel initiate coverage for @GenIncode with a BUY rating - "With US launch planned for 2022 and potential for sales to reach $225m by 2028E, we see significant upside to the shares." Target price 175p #GENI"


I'd be interested to know what profit could be earned from that US$225M. of potential GENI revenues in 2028.

Health sector margins can be extremely high when there is strong IP and barriers to entry like GENI's.

Bioventix (BVXP) for example has pre-tax profit margins of 74%:

18/10/2021 06:00 UK Regulatory (RNS & others) Bioventix Plc Results for the year ended 30 June 2021 LSE:BVXP Bioventix Plc
"... Highlights:
* Revenue up 6% to £10.93 million (2020: £10.31 million)
* Profit before tax down 1% to £8.12 million (2020: £8.23 million) ..."


And at its current share price of 3,095p, BVXP has a market cap. of £161.23M., i.e. 14.75 times full year revenues.


Applying that ratio to GENI'S potential 2028 sales of US$225M. would give a market cap. of US$3,318M.: i.e. about £2.5 billion at current exchange rates.

Compared to GENI's current market cap. of £27.31 million at 28.5p.


Bioventix (BVXP):

[hedgehog 100] 26/1/2022 17:03

We're probably in the close period ahead of GENI's final results for the year ending 31.12.21, which would prevent the directors from buying at the current depressed s.p.

David Evans should be able to buy though, as he's no longer a director, provided he's not in possession of inside information.

And interestingly, D.E. has just transferred £309K. of shares in his IIG life sciences fund into his SIPP, which is a sign that he considers IIG shareas to be undervalued at their current depressed share price.

24/01/2022 08:45 UKREG Intuitive Investments Group plc Director Dealing

"Intuitive Investments Group plc (AIM:IIG), ("IIG" or the "Company"), announces that Mr David Evans, Executive Chairman of Intuitive Investment Group, has transferred 1,742,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from a nominee account to his SIPP. The Ordinary Shares were transferred at a price of 17.75p and remain beneficially owned by Mr Evans.

Accordingly, Mr Evans's total holding in the Company remains unchanged at 5,000,000 Ordinary Shares, representing approximately 12.37 per cent. of the Company's issued share capital."



Intuitive Investments (IIG):

[hedgehog 100] 23/1/2022 11:11

21/01/2022 07:00 UK Regulatory (RNS & others) GENinCode PLC Proposed independent directorate appointment LSE:GENI Genincode Plc

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its intention to appoint Professor Huon Gray CBE, to the Board as an independent non-executive director.

Huon has 30 years' experience practising as a consultant cardiologist for the NHS and private sector, with particular experience in cardiovascular risk assessment and interventional cardiology. Huon served as the National Clinical Director for Heart Disease in the Department of Health and then NHS England from 2012-2019, advising government, all party parliamentary groups, the NHS and NICE on healthcare delivery and reform. He is a former President of the British Cardiac Society (now the British Cardiovascular Society) and was previously Chair of the International Committee of the American College of Cardiology.

In 2018, Huon was awarded the honour of Master of the American College of Cardiology, the only recipient outside of the US, and the Mackenzie Medal by the British Cardiovascular Society in 2014 in recognition of his services to British cardiology. In 2019, he was made a CBE for his services to cardiology.

Huon's exposure to the US healthcare system through his work with the American College of Cardiology over 15 years, in roles such as Trustee and Chair of its Governance Committee, will support the Company as it targets the US as one of its primary markets. Additionally, during Huon's tenure at NHS England, he acted as a liaison with industry and Academic Health Science Networks, helping deliver healthcare in the NHS through encouraging the adoption of innovation and new technology.

Huon will be appointed to the board of GENinCode following finalisation of the terms of his appointment and the completion of the necessary regulatory due diligence in accordance with the AIM Rules.

In addition, GENinCode anticipates appointing an additional independent non-executive director in the short-term. A suitably qualified US-based candidate has been identified that is an experienced healthcare industry and US FDA regulatory veteran and whom the Board believes will be very additive to GENinCode's future.

Further announcements will be made at the appropriate time.

Bill Rhodes, Chair of GENinCode Plc, commented: "We are delighted to have Huon join the Board, subject to completion of the necessary formalities. Huon has extensive and expansive experience in clinical cardiology and through his relationships globally, and particularly in the US and the UK, coupled with his deep appreciation for the benefits both patients and practitioners will gain from the use of our products, there is no question he will add tremendous value to the Board, the Company and our shareholders."

Matthew Walls, CEO of GENinCode Plc, added: "Huon's background and vast experience as a leading cardiologist in both the UK and the US will be invaluable to the Company as we look towards commercialisation later in 2022. Importantly, he shares our excitement about the potential of the Company's portfolio of products to drastically improve the current standard of care worldwide."

Professor Huon Gray CBE commented: "I am delighted to be asked to join the Board of GENinCode at this important stage. Cardiovascular risk assessment in the US and UK currently comprises a series of questions related to conventional risk factors, with no genetic risk assessment. This is despite family history being one of the most significant contributing risk factors to an individual's likelihood of suffering from cardiovascular disease. Consequently, the Company's portfolio of diagnostic products have significant potential to improve the standard of care for millions who every year suffer from cardiovascular disease."

[barbello] 21/1/2022 18:28

Impressive appointment, with another soon. Builds my confidence.

[hedgehog 100] 13/1/2022 15:20

RENX dual-listed in the US in the summer of 2020, floating at the equivalent of over 4 times its AIM IPO price only 20 months before.

This could be the 'template' for GENI.

Which could equate to GENI dual-listing in the US early next year, at about 200p/share equivalent.


18/05/2020 06:00 UK Regulatory (RNS & others) Renalytix AI PLC Proposed dual-listing on Nasdaq LSE:RENX Renalytix Plc
"Renalytix AI plc (LSE : RENX ), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs , announces that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of American Depositary Shares, each of which will represent one or a number of the Company's ordinary shares, on the Nasdaq Stock Market (the "Offering").
The number of securities to be offered and the price for the proposed Offering have not yet been determined. The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions . Shareholders and potential investors should note that the potential Offering may or may not proceed."


25/06/2020 06:00 UK Regulatory (RNS & others) Renalytix AI PLC Public filing re. Nasdaq dual-listing and offering LSE:RENX Renalytix Plc


13/07/2020 11:01 UK Regulatory (RNS & others) Renalytix AI PLC Launch of Global Offering and application to list LSE:RENX Renalytix Plc


21/07/2020 16:30 UK Regulatory (RNS & others) Renalytix AI PLC Closing of Global Offering and resulting TVR LSE:RENX Renalytix Plc
"Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence -enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs , today announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares, including 5,485,000 American Depositary Shares ("ADSs") at a price of US$13.50 per ADS and 30,000 ordinary shares at a price of GBP5.37 per ordinary share (at an exchange rate of GBP:USD 1:1.2563), for aggregate gross proceeds of approximately US$74.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by RenalytixAI. Each ADS offered represents two ordinary shares of the Company. The ADSs were offered in a registered public offering in the United States and the Company's ordinary shares were offered in a concurrent private placement in Europe and other countries outside of the United States (together, the "Global Offering"). In addition, RenalytixAI has granted the underwriters a 30-day option to purchase up to an additional 822,750 ADSs at the initial offering price per ADS less underwriting discounts and commissions.
The ADSs began trading on the Nasdaq Global Market under the symbol "RNLX" on 17 July 2020. RenalytixAI's ordinary shares are admitted to trading on the AIM market of London Stock Exchange plc ("AIM") under the symbol "RENX". Application has been made for the new ordinary shares issued in Global Offering to be admitted to trading on AIM and it is expected that admission will become effective and dealings in the new ordinary shares will commence at 8:00 a.m. (BST) on 22 July 2020.
J.P. Morgan and Stifel acted as joint global coordinators and joint book-running managers for the Global Offering. ..."

[hedgehog 100] 13/1/2022 14:58

The comparison of GENI to RENX before it ten-bagged is compelling.

Note that GENI and RENX even have the same NOMAD (nominated advisor), i.e. Stifel.

"Nominated Adviser and Joint Broker
Stifel Nicolaus Europe Limited
4th Floor, 150 Cheapside
London
EC2V 6ET"


"Nominated Advisor
Stifel Nicolaus Europe Limited
150 Cheapside
London
EC2V 6ET"

[diversification] 10/1/2022 18:41

It’s at this stage that its worth reevaluating some of the key milestones that we can expect in the coming weeks/months.

- Two American collaborations (Covid and CardioIncode)
- Thromboincode study publication (Covid)
- Ukca approval (imminent)
- Lipidincode commercial progress with NHS
- Lipidincode direct competitor NHS comparison
- Pharma discussions
- German Collaboration

Plenty for the market to build momentum on. Today was the official starting point.

[hedgehog 100] 10/1/2022 17:38

Well, GENI has finished the day up 1.75p (5.5%), at 33.75p.

The share price only rose today, in four steps, with no fallbacks.

And this is actually GENI's best one day rise since August, as is befitting today's good news.

Just two or three more days like this and we could be back in the upper 30s, which would be a good base from which to build further.

[mr. t] 24/12/2021 09:36

Thanks. I've only bought a starter stake but will be ready to buy more if the story unfolds like we hope :)